Educational research & price index · Independent Janoshik & MZ Biolabs COA verification
Guide|30 CitationsImmunity & GutFemale-friendly

Thymosin Alpha-1 Dosing Protocol: Clinical Research

Also known as: Zadaxin, Thymalfasin, T-Cell Immune Modulator

Dose Range
1.6 mgResearch range
0Typical research window: 1.6 mg2.5 mg

Studied in published research — not a medical recommendation. Primary protocol (Immune Enhancement Protocol): 1.6 mg, Twice weekly.

Protocol at a Glance
How Often
2–3× weekly

Twice weekly

A Typical Run
6 months

Research-reported range; the linked study used a different dose or units.

How It's Taken
Vial

Subcutaneous

Evidence
Clinical Trials

Published peer-reviewed research & clinical protocols

Half-Life & 72-Hour Clearance Shape
Not established

No verified human half-life on file for this compound

0h18h36h54h72h
On Your SyringeU-100 Insulin Syringe

A vial is powder until you add bacteriostatic water. Change the vial size or water volume below to see the exact unit mark on your syringe.

5 mg vial · 2 mL water · 0.5 mL syringe
Concentration: 2.5 mg in every mL (25 mcg per unit)
0u10u20u30u40u50u
Low end: 1.6 mg64 units

All U-100: 100 units = 1 mL. 3 doses in the vial at the low end.

Track the doses you run

Save Thymosin Alpha-1 (Tα1) to your personal protocol list to log your custom dosage, syringe units, ON/OFF cycle dates, and lab notes across devices.

Verified Peptide Vial Suppliers · Sorted by Real $/mg•Checked Nov 11, 2026

Thymosin Alpha-1 (Tα1) supplier & $/mg comparison.

Source:
Max $/mg:
Sort:
Ascension Peptides50% OFF AUTO-APPLIED
Batch COAs (Kovera Labs, MZ Biolabs) on product page
US Domestic Vial
50% Off First Order Link
$35.50 net$71.00
10mg Lyophilized Vial
$3.55/mg$7.10/mg retail
Polaris Peptides
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026)
$65.00
10mg vial
$6.50/mg
Elite Research USA
Batch COA on product page
US Domestic Vial
List price
$78.00
10mg vial
$7.80/mg
Pure Peptides
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026); code PEPTIDE9544 takes 10% off at checkout
$93.00
10mg vial
$9.30/mg
Direct Peptides
COA per store product page
US Domestic Vial
List price (last verified Nov 4, 2026; store now requires sign-in)
$99.00
10mg vial
$9.90/mg
Swift Peptides
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026)
$109.99
10mg vial
$11.00/mg
Peptyes
Horizon Analytical UPLC-MS COA, lot DPS-1947064 (99.32%); COA names Privilege Bio Labs (Peptyes says: its manufacturer)
US Domestic Vial
List price (verified Nov 11, 2026); code PEPTIDEPROTOCOLS takes 10% off at checkout
$126.00
10mg vial
$12.60/mg
Biotech Peptides
COA per store product page
US Domestic Vial
List price (verified Oct 31)
$130.00
10mg vial
$13.00/mg
Limitless Peptides
COA per store product page
US Domestic Vial
Code: PEPTIDEPROTOCOLS
$130.00
10mg vial
$13.00/mg
BioLongevity Labs
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026)
$129.97
10mg vial
$13.00/mg
Core Peptides
COA per store product page
US Domestic Vial
List price (verified Oct 31)
$149.00
10mg vial
$14.90/mg
Sorted strictly by calculated $/mg or 2026 COA score. Only research peptide vial suppliers are included in $/mg benchmarks.
Full Verified $/mg Index →

At a Glance · 2026 FDA / 503A / WADA / Evidence Profile

Phase 2/3 Clinical TrialsTier 1 — Human Phase 3 RCT / Approved
Pharmacological Class
Synthetic Bioactive Signaling Peptide
Administration Route
Under-the-skin injection (Subcutaneous)
2026 FDA & 503A Status
Active Phase 2/3 human clinical trials in 2026; not yet FDA-approved for commercial prescription or 503A bulk pharmacy compounding. Sold strictly as an analytical laboratory reference standard.
WADA Sport Status
Prohibited at All Times (WADA S0 Unapproved Substances & S2.2 Peptide Hormones, Growth Factors & Mimetics)
Evidence Tier
Tier 1 — Human Phase 3 RCT / Approved: Multi-center randomized controlled human clinical trials (Phase 3) and/or regulatory approval
What is a Peptide?

A short chain of amino acids (2-50) linked by peptide bonds. Smaller than proteins. Your body produces thousands of peptides naturally as signaling molecules that regulate everything from appetite to healing. Therapeutic peptides mimic or enhance these natural signals.

Thymosin Alpha-1 (Tα1) is the same active compound as Zadaxin (SciClone Pharmaceuticals). Not FDA approved in the US.

EDUCATIONAL AND RESEARCH REFERENCE ONLY — NOT MEDICAL ADVICE. Thymosin Alpha-1 (Tα1) is not FDA approved for human use (unless specified above). This information does not constitute medical advice.

Overview

Thymosin Alpha-1 is a peptide fragment derived from prothymosin alpha. It has been studied for its immunomodulatory properties and effects on T-cell function.

Mechanisms of Action

  • Enhances T-cell differentiation
  • Modulates cytokine production
  • Supports dendritic cell maturation
  • Regulates immune response balance

Research Protocols

Summaries of published research. For educational purposes only.

Protocol NameSourceDoseFrequencyDurationRouteEvidenceLinkSave
Immune Enhancement Protocol
reported protocol
1.6 mgTwice weekly6 monthsSubcutaneoushuman
Baseline & Mid-Cycle Biomarker Bloodwork Panel

Systemic Inflammation, Tissue Repair & Immune Biomarker Panel (Thymosin Alpha-1 (Tα1))

Objective inflammatory, hematologic, and trace-mineral markers to quantify connective-tissue recovery, cytokine resolution, and organ safety.

Draw fasted morning labs at Baseline (Day 0) and Mid-Cycle (Week 6–8)

hs-CRP (High-Sensitivity C-Reactive Protein)

Day 0 + Wk 6–8

Why track at baseline: Quantifies baseline systemic IL-6/NF-κB inflammatory burden from tendon, joint, gut, or vascular injury.

Week 6–8 check: Target <1.0 mg/L (optimal <0.5 mg/L) by Week 6–8 as tissue inflammation resolves.

ESR (Sedimentation Rate) & Ferritin

Day 0 + Wk 6–8

Why track at baseline: Tracks chronic connective-tissue and autoimmune/mucosal inflammatory activity alongside iron stores.

Week 6–8 check: Downward trend in ESR confirming structural resolution rather than temporary analgesic masking.

CBC with Differential (WBC, Neutrophil/Lymphocyte Ratio)

Day 0 + Wk 6–8

Why track at baseline: Evaluates innate/adaptive immune balance (especially for Thymosin Alpha-1, Thymosin Beta-4, LL-37 & KPV).

Week 6–8 check: Balanced lymphocyte count and improved Neutrophil-to-Lymphocyte Ratio (NLR 1.2–2.0).

CMP (Liver/Kidney) + Serum Copper & Zinc Ratio

Day 0 + Wk 6–8

Why track at baseline: Verifies baseline hepatic/renal function and checks Copper:Zinc balance before GHK-Cu / GLOW / KLOW protocols.

Week 6–8 check: Maintain 1:1 to 1.2:1 Zinc-to-Copper equilibrium and normal transaminases/creatinine.

Test before and during your protocol: one baseline panel of 100+ Quest biomarkers covering the markers above, plus a mid-cycle retest. No doctor visit required.Code SPAMBASSADOR
Get baseline bloodwork at Superpower

Related Studies

27 Human3 Animal

It represents a promising therapeutic approach to counteract age-related immune dysfunction and inflammation, potentially by slowing the aging process. Further research is needed to validate its long-term efficacy and safety in geriatrics.

Limitations: No placebo control reported. Review article — no new primary data.

2025|International journal of molecular sciences
PubMed

Both exogenously supplied and adenovirus-produced T&#x3b1;1 orchestrate TAM reprogramming and enhance the antitumor efficacy of ADV via CD8+ T&#xa0;cells, showing promising prospects for clinical translation. Our findings provide inspiration for improving oncolytic adenovirus combination therapy and designing oncolytic engineered adenoviruses.

Limitations: No placebo control reported.

2024|Cell reports. Medicine
PubMed

Although PDD presents challenges such as hit validation and target deconvolution, significant achievements have been reached in the era of big data. This article explores the experiences of researchers testing the effect of a thymic peptide hormone, thymosin alpha-1, in preclinical and clinical settings and discuss how its therapeutic utility in the precision medicine era can be accommodated within the PDD framework.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

2024|Frontiers in medicine
PubMed

More high-quality randomised controlled trials are needed to further confirm Thymosin alpha 1 efficacy. Key Words: Thymosin alpha 1, Efficacy, Acute exacerbation of chronic obstructive pulmonary disease, Meta-analysis.

Limitations: No placebo control reported. Review article — no new primary data.

2024|Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
PubMed

Contrary to the FDA's restriction on T&#x3b1;1 and 21 additional peptides in 2023, our analysis reveals consistent evidence of T&#x3b1;1's safety and efficacy. The peptide has demonstrated significant effectiveness in treating various conditions, including COVID-19, autoimmune disorders, and cancer.

Limitations: No placebo control reported. Review article — no new primary data.

2024|Alternative therapies in health and medicine
PubMed

A total of 49 patients were included in this analysis. Compared with control patients, the incidence of clinical recovery was higher for treated patients with either baseline low-flow oxygen (subdistribution hazard ratio, 1.48 [95% confidence interval, .68-3.25]) or baseline high-flow oxygen (1.28 [.35-4.63]), although neither difference was significant.

Limitations: Preliminary/pilot study — needs larger trials. No placebo control reported.

2023|The Journal of infectious diseases
PubMed

For treatment of malignancies, the combination of T&#x3b1;-1 and chemotherapy has a strong synergistic effect by enhancing the anti-tumor immune response. On the basis of the pleiotropic effect of T&#x3b1;-1 on immune cells and the promising results of preclinical studies, T&#x3b1;-1 may be a favorable immunomodulator to enhance the curative effect and decrease immune-related adverse events of immune checkpoint inhibitors to develop novel cancer therapies.

Limitations: No placebo control reported.

2023|International immunopharmacology
PubMed

In severe sepsis, for example, sepsis-induced immunosuppression is increasingly recognized as the overriding immune dysfunction in these vulnerable patients [4] and there is now agreement that many patients with severe sepsis survive the first critical hours of the syndrome but eventually die later due to patients' immunosuppression which make the system difficulty to fight the primary bacterial infection, decreased resistance to secondary nosocomial infections, and reactivation of viral infections [5]. T&#x3b1;1 has been shown to restore immune functions and help to reduce mortality in patients with severe sepsis.

Limitations: No placebo control reported.

2023|International immunopharmacology
PubMed

Pooled data from 8 studies indicated that moderate to critical Covid-19 patients who were receiving thymosin alpha-1 therapy had significantly lower mortality from COVID-19 (RR 0.59; 95% CI 0.37-0.93, p&#x2009;=&#x2009;0.02, I2&#x2009;=&#x2009;84%), but without any difference in the needs for mechanical ventilation (RR 0.83; 95% CI 0.48-1.44, p&#x2009;=&#x2009;0.51, I2&#x2009;=&#x2009;74%) and hospital length of stay (MD 2.32; 95% CI -&#xa0;0.93, 5.58, p&#x2009;=&#x2009;0.16, I2&#x2009;=&#x2009;94%) compared to placebo. The benefits of thymosin alpha-1 on the mortality rate were significantly affected only by sample size (p&#x2009;=&#x2009;0.0000) and sex (p&#x2009;=&#x2009;0.0117).

Limitations: Review article — no new primary data.

2023|Inflammopharmacology
PubMed

In conclusion, T&#x3b1;-1 improved the curative effect of chemotherapy by reversing M2 polarization of efferocytosis-activated macrophages, suggesting that T&#x3b1;-1 injection immediately after chemotherapy may contribute to highly synergistic antitumor effects in patients with breast cancer. SIGNIFICANCE: Thymosin &#x3b1;-1 improves the curative effect of chemotherapy by reversing efferocytosis-induced M2 polarization of macrophages via activation of a TLR7/SHIP1 axis.

Limitations: No placebo control reported.

2022|Cancer research
PubMed

All crude outcomes, including non-recovery rate (65/306 vs. 290/1,976, p = 0.003), in-hospital mortality rate (62/306 vs.

Limitations: No placebo control reported.

2021|Frontiers in immunology
PubMed

In this review, we discuss key literature on the background knowledge and current clinical uses of thymosin alpha 1. Considering the known biochemical properties including antibacterial and antiviral properties, time-honored applications, and the new promising findings regarding the use of thymosin, we believe that thymosin alpha 1 deserves further investigation into its antiviral properties and possible repurposing as a treatment against severe acute respiratory syndrome coronavirus-2.

Limitations: No placebo control reported. Review article — no new primary data.

2020|World journal of virology
PubMed

This study also calls into question the autophagy modulator cysteamine, since no rescue of mutant CFTR function was detected following treatment with cysteamine, while deleterious effects were observed when bronchial epithelia were exposed to cysteamine plus the antioxidant food supplement EGCG. Although these studies do not exclude the possibility of beneficial immunomodulatory effects of thymosin &#x3b1;-1, they do not support its utility as a corrector of F508del-CFTR.

Limitations: No placebo control reported.

2020|Scientific reports
PubMed

Also, the present studies on T&#x3b1;1 treatment are not able to focus on the immunosuppressive individuals. We believe that selecting septic patients with immunosuppression will be more likely to reveal the efficacy of T&#x3b1;1 in future trials.

Limitations: No placebo control reported. Review article — no new primary data.

2019|Expert opinion on biological therapy
PubMed

EXPERT OPINION: Low serum Ta1 levels are predictive and/or associated with different pathological conditions. In case of Ta1 treatment, it is crucial to know the patient's baseline serum Ta1 level to establish effective treatment protocols and monitor their effectiveness over time.

Limitations: No placebo control reported. Review article — no new primary data.

2019|Expert opinion on biological therapy
PubMed

From thymus to cystic fibrosis: the amazing life of thymosin alpha 1. (Expert opinion on biological therapy, 2019)

Limitations: Animal study only — human translation uncertain.

2019|Expert opinion on biological therapy
PubMed

Extensive studies in both the preclinical and clinical setting will be summarized in the subsequent sections. These studies have demonstrated improvements in immune system cell subsets and the potential of Ta1 for the treatment of a range of diseases.

Limitations: No placebo control reported. Review article — no new primary data.

2017|Vitamins and hormones
PubMed

This review reports the present knowledge on the in vitro and in vivo studies concerning the use of thymosin alpha 1 in HIV-1 infection. Recent findings and future perspectives of therapeutic intervention are discussed.

Limitations: No placebo control reported. Review article — no new primary data.

2017|Future microbiology
PubMed

The differing structures of thymosin alpha and thymosin beta proteins have been studied by circular dichroism, nuclear magnetic resonance, and crystallographic methods in order to better understand the role of these proteins. In this structural biology review the structures of prothymosin, parathymosin, thymosin alpha-1, and several beta thymosin proteins, in both native states and under secondary structure-inducing conditions are discussed.

Limitations: No placebo control reported. Review article — no new primary data.

2017|Vitamins and hormones
PubMed

Most of the combination therapy of T&#x3b1;-1 plus either lamivudine or IFN-&#x3b1; showed better effects on HBV DNA suppression and HBeAg seroconversion. Presently, clinical studies of T&#x3b1;-1 combined with entecavir on the treatment of HBV-cirrhosis are ongoing.

Limitations: No placebo control reported.

2016|Expert opinion on biological therapy
PubMed

In the most recent clinical trials T&#x3b1;1 has been used at higher doses than those commonly used in the past showing a direct proportionality between the dose and the effect. The safety profile of T&#x3b1;1 is excellent and it is virtually devoid of toxicity.

Limitations: No placebo control reported. Review article — no new primary data.

2016|Expert opinion on biological therapy
PubMed

Several studies were conducted and showed that Talpha1 ameliorate the performanc of influenza vaccination in elderly and subjects at risk. Although further studies on co-adjuvants are necessary, the future prospects of producing ever more efficacious influenza vaccines appear very promising.

Limitations: No placebo control reported. Review article — no new primary data.

2011|Journal of preventive medicine and hygiene
PubMed

It has been shown to trigger maturational events in lymphocytes, to augment T-cell function, and to promote reconstitution of immune defects. Studies are underway in both monotherapy and combination therapy with thymalfasin and interferon and results are promising.

Limitations: No placebo control reported. Review article — no new primary data.

2008|Journal of gastroenterology and hepatology
PubMed

It has been shown to trigger maturational events in lymphocytes, to augment T-cell function, and to promote reconstitution of immune defects. Studies are underway in both monotherapy and combination therapy with thymalfasin and interferon and results are promising.

Limitations: No placebo control reported. Review article — no new primary data.

2005|Journal of gastroenterology and hepatology
PubMed

Clinical trials of TA1 for chronic hepatitis B or C have had mixed results. TA1 may be useful as monotherapy for hepatitis B or in combination with IFN-alpha 2b for hepatitis C, but its effects on morbidity and mortality remain to be seen.

Limitations: Review article — no new primary data.

2001|American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
PubMed

Our work to reverse thymic involution in hydrocortisone-treated, aged mice with interleukins, thymosin alpha 1, and zinc will be reviewed. Recent efforts to treat successfully immune deficiency in aged and cancer-bearing humans will be presented.

Limitations: No placebo control reported. Review article — no new primary data.

1998|Annals of the New York Academy of Sciences
PubMed

Finally, "thymomimetic" peptides like thymosin alpha 1 or drugs like levamisole or isoprinosine alone or in conjunction with interleukins may augment TH-1 and DTH responses. These approaches are seeing increasing emphasis in new treatment strategies for cancer and infections like HIV.

Limitations: No placebo control reported. Review article — no new primary data.

1995|International journal of immunopharmacology
PubMed

Clinical applications of thymosin alpha-1. (Cancer investigation, 1994)

Limitations: No placebo control reported. Review article — no new primary data.

1994|Cancer investigation
PubMed

Thymic stromal cells contribute, at minimum, IL1. These various interleukin and thymic hormone influences can be envisioned to operate in a synergistic interactive network to carry the evolving T-cell through its stepwise development to a mature T-cell.(ABSTRACT TRUNCATED AT 250 WORDS).

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

1992|International journal of immunopharmacology
PubMed

Community Outcomes

Community Data Coming Soon

Aggregate community outcomes will be displayed here once we have more reports. Be one of the first to share your experience!

Outcomes are self-reported and unverified. They represent individual experiences and may not reflect typical results.

Important Warnings

  • •Prescription drug in some countries
  • •Consult healthcare provider
Sourcing, Diagnostic Bloodwork & Telehealth Pathways

Where to get Thymosin Alpha-1 (Tα1), baseline labs & clinician oversight.

Full Thymosin Alpha-1 (Tα1) $/mg comparison →
50% OFF AUTO-APPLIED$3.55/mg net

Ascension Peptides (US Vials)

MZ Biolabs & SafeCert COA-verified US domestic single vials with 50% off auto-applied for new customers.

MZ Biolabs COA (Grade A)Claim 50% Off
Verified Vial SuppliersGrade A COA

SwissChems & Limitless Biotech

Same-day US domestic lyophilized vials, oral capsules, and endotoxin-screened nasal sprays (15% off Limitless w/ code PEPTIDEPROTOCOLS).

LABS & 503A CLINICS$199/yr Labs · Rx Consult

Superpower Labs & 503A Telehealth

Bloodwork, not a vial store. Get a baseline panel (100+ Quest biomarkers: metabolic, lipids, hormones, inflammation, kidney/liver) before you start a peptide protocol, then retest mid-cycle to see what actually changed.

Code:SPAMBASSADOR

Where to buy Thymosin Alpha-1 (Tα1): best verified price

Prices checked Nov 11, 2026 · sorted by $/mg · RUO

  1. 1. Ascension Peptides — $3.55/mg (10mg Lyophilized Vial, $35.50)
  2. 2. Polaris Peptides — $6.50/mg (10mg vial, $65.00)
  3. 3. Elite Research USA — $7.80/mg (10mg vial, $78.00)

Where is the cheapest place to buy Thymosin Alpha-1 (Tα1)?

As of Nov 11, 2026, the lowest verified US domestic single-vial price we found is Ascension Peptides at $3.55/mg (10mg Lyophilized Vial, $35.50 after the 50% new-customer partner-link discount). We compared 11 US suppliers with live, checked prices.

How much does Thymosin Alpha-1 (Tα1) cost per mg?

Verified US domestic prices currently range from $3.55/mg to $14.90/mg depending on supplier and vial size. Larger vials usually lower the $/mg.

How are these prices verified?

Each price is read from the supplier's own product page or store data and divided by the vial's mg. Suppliers we could not verify are left out rather than estimated. Tables sort strictly by $/mg, never by partner status. Prices are re-checked weekly on our price index.

Is Thymosin Alpha-1 (Tα1) approved for human use?

Products from these suppliers are sold for laboratory research use only (RUO). This page is an educational price reference, not medical advice.

All compounds $/mgWeekly $/mg price indexReconstitution calculatorFree cheat sheet

FREE 1-PAGE PDF CHEAT SHEET

Peptide Reconstitution & U-100 Syringe Cheat Sheet

Printable U-100 insulin syringe draw chart for 5mg–50mg vials, plus our weekly $/mg price-drop brief.

Unsubscribe anytime.Direct PDF Download

Trusted Voices

X/Twitter accounts discussing this peptide

Related Peptides

Popular Stacks

Vendor vs vendor: price per mg

Head-to-head $/mg on shared compounds. Prices verified Nov 11, 2026.

Compound vs compound: BPC-157 vs TB-500 · Tirzepatide vs Semaglutide · Retatrutide vs Tirzepatide · Wolverine Blend vs GLOW Blend · Semax vs Selank · KLOW Blend vs GLOW Blend · MOTS-c vs SS-31 · Sermorelin vs Ipamorelin · Retatrutide vs Semaglutide · Tesamorelin vs Sermorelin · All compounds $/mg →

Common questions

How many peptides are in the database?

100 compound pages, each with dosing references, reconstitution math and price per mg where a verified vendor price exists.

Where can I compare peptide prices?

Each compound page shows verified $/mg by vendor; the vendor-vs-vendor pages above compare two vendors across their shared compounds.